# GSK2190915A - Bioavailability Study

> **NCT02224521** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 67 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** GSK2190915 Solution.
- **DRUG:** GSK2190915 Granule Capsule (A)
- **DRUG:** GSK2190915 Semi-solid Lipid Capsule (B)
- **DRUG:** GSK2190915 Liquid Lipid Capsule (C)
- **DRUG:** GSK2190915 Milled Tablet
- **DRUG:** GSK2190915 Micronised Tablet

## Key facts

- **NCT ID:** NCT02224521
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-20
- **Primary completion:** 2010-06-08
- **Final completion:** 2010-06-08
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02224521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02224521, "GSK2190915A - Bioavailability Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02224521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*